HMBD-001 | Hummingbird Bioscience

WCLC 2024: A Phase Ib Study to Evaluate HMBD‑001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD‑001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers

Continue Reading
AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

Continue Reading
ESMO 2023: A CRUK phase I/IIA, first in human dose‐escalation and expansion trial of HMBD‐001 (an anti‐HER3 antibody) in patients with advanced HER3 positive solid tumours

HMBD-001 is Hummingbird Bioscience’s proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and…
Continue Reading
WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC

Continue Reading
AACR 2023: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker selected pre-clinical models of squamous cell carcinomas

Continue Reading
AACR-NCI-EORTC Virtual International Conference 2021: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1 fusion driven cancers

Continue Reading
Molecular Cancer Therapeutics, AACR Journals: 10D1F, an anti-HER3 antibody that uniquely blocks the receptor heterodimerization interface, potently inhibits tumor growth across a broad panel of tumor models

Continue Reading
Cancer Research, Volume 77, Issue 13 Supplement, AACR Journals: HMBD-001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors

Continue Reading

What are you looking for?